Research Article
Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma
Table 1
The baseline characteristics of the LIHC patients from the TCGA database.
| Characteristic | Low expression of PRC1 | High expression of PRC1 | |
| n | 187 | 187 | | Age, (%) | | | 0.006 | ≤60 | 75 (20.1%) | 102 (27.3%) | | >60 | 112 (30%) | 84 (22.5%) | | Gender, (%) | | | 0.377 | Female | 56 (15%) | 65 (17.4%) | | Male | 131 (35%) | 122 (32.6%) | | Race, (%) | | | 0.044 | Asian | 66 (18.2%) | 94 (26%) | | Black or African American | 9 (2.5%) | 8 (2.2%) | | White | 101 (27.9%) | 84 (23.2%) | | Tumor status, (%) | | | 0.005 | Tumor free | 115 (32.4%) | 87 (24.5%) | | With tumor | 63 (17.7%) | 90 (25.4%) | | T stage, (%) | | | 0.017 | T1 | 106 (28.6%) | 77 (20.8%) | | T2 | 41 (11.1%) | 54 (14.6%) | | T3 | 32 (8.6%) | 48 (12.9%) | | T4 | 5 (1.3%) | 8 (2.2%) | | N stage, (%) | | | 0.624 | N0 | 122 (47.3%) | 132 (51.2%) | | N1 | 1 (0.4%) | 3 (1.2%) | | M stage, (%) | | | 0.361 | M0 | 130 (47.8%) | 138 (50.7%) | | M1 | 3 (1.1%) | 1 (0.4%) | | Pathologic stage, (%) | | | 0.009 | Stage I | 99 (28.3%) | 74 (21.1%) | | Stage II | 40 (11.4%) | 47 (13.4%) | | Stage III | 32 (9.1%) | 53 (15.1%) | | Stage IV | 4 (1.1%) | 1 (0.3%) | | BMI, (%) | | | 0.207 | ≤25 | 83 (24.6%) | 94 (27.9%) | | >25 | 87 (25.8%) | 73 (21.7%) | | AFP(ng/ml), (%) | | | < 0.001 | ≤400 | 126 (45%) | 89 (31.8%) | | >400 | 19 (6.8%) | 46 (16.4%) | | Child-Pugh grade, (%) | | | 1.000 | A | 122 (50.6%) | 97 (40.2%) | | B | 12 (5%) | 9 (3.7%) | | C | 1 (0.4%) | 0 (0%) | | Age, median (IQR) | 64 (54.5, 69.5) | 59 (50.25, 67.75) | 0.005 |
|
|